Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (AU:TLX)
ASX:TLX
TLX Stock Chart & Stats
AU$16.17
-AU$0.59(-2.38%)
At close: 4:00 PM EST
AU$16.17
-AU$0.59(-2.38%)
Day’s Range― - ―
52-Week RangeAU$13.30 - AU$31.97
Previous CloseN/A
Volume456.62K
Average Volume (3M)2.48M
Market Cap
$5.56B
Enterprise ValueAU$8.56B
Total Cash (Recent Filing)$207.16M
Total Debt (Recent Filing)$418.25M
Price to Earnings (P/E)329.9
Beta1.05
Next Earnings
Feb 19, 2026EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding338,458,830
10 Day Avg. Volume2,192,814
30 Day Avg. Volume2,481,684
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)14.35
Price to Sales (P/S)10.41
P/FCF Ratio906.02
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue7.21
Enterprise Value/Gross Profit12.69
Enterprise Value/Ebitda99.84
Forecast
1Y Price Target
$26.95Price Target Upside66.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Regulatory AdvantageThe CMS granted Gozellix Transitional Pass-Through (TPT) status, which is expected to offset a portion of future impact to Telix's prostate diagnostics franchise.
Revenue GrowthTelix pre-reported Q3 total revenue of $206MM, ahead of expectations as the PSMA diagnostic franchise volume grew +3%.
Revenue Guidance IncreaseThe company increased total revenue guidance by $25MM at the midpoint to $800-820MM, indicating confidence in future performance.
Bears Say
Operating CostsHigher-than-expected operating costs relative to consensus expectations.
Pricing PressureThe 3% volume increase in PSMA diagnostics was offset by expected pricing pressure that was likely driven by Illuccix's loss of transitional pass-through status and competition.
Stock PerformanceTLX's share price has declined by 28% from 22 Jul-25, underperforming the ASX200 by 32%.
Telix Pharmaceuticals News
TLX FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest share price was AU$13.30 and its highest was AU$31.97 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is $5.56B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 19, 2026 which is in 112 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Aug 20, 2025. The company reported AU$0.015 earnings per share for the quarter, missing the consensus estimate of AU$0.281 by -AU$0.266.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.36.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 338,458,830 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of AU$0.015 in its last earnings report, missing expectations of AU$0.281. Following the earnings report the stock price went up 6.974%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:TLX
Telix Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.95 (66.68% Upside)
$26.95 (66.68% Upside)
Blogger Sentiment
Bullish
AU:TLX Sentiment 94%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.03%
12-Months-Change
Fundamentals
Return on Equity
3.21%
Trailing 12-Months
Asset Growth
138.86%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals (TLX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of cancer and other serious diseases. The company specializes in radiopharmaceuticals, which are a combination of pharmaceuticals and radioactive isotopes, aimed at targeting and treating tumors while minimizing damage to surrounding healthy tissue. Telix operates primarily in the oncology sector, with a portfolio that includes products designed for imaging and therapeutic applications, such as prostate cancer and renal cancers.
TLX Company Deck
TLX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance in terms of revenue growth, product expansion, and strategic acquisitions, highlighting the company's robust cash position and pipeline advancements. However, challenges such as SEC inquiries, gross margin pressure, and competitive pricing pressures were noted.View all AU:TLX earnings summariesTLX Stock 12 Month Forecast
Average Price Target
AU$26.95
▲(66.68% Upside)
Technical Analysis
Clinuvel Pharmaceuticals
―
Mesoblast Limited
―
Neuren Pharmaceuticals Limited
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Options Prices
Currently, No data available
---